Trial sponsors

4441 lead sponsors across 22,904 registered phase 2 and 3 studies and 6086 curated trials: 1246 companies, 181 cooperative groups and 1168 institutions, plus names not yet mapped. Filter by cancer to see who runs the most trials in it.

4,441 sponsors

#
1	National Cancer Institute (NIH) Government or charity	995	105 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H..+102	890	149	804	100
2	MD Anderson Cancer Center Institution	638	42 A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer+39	596	40	570	120
3	AstraZeneca Company	606	256 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With +253	350	297	198	67
4	Sun Yat-sen University Cancer Center Institution	548	106 A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer+103	442	142	346	113
5	Merck & Co. (MSD) Company	480	178 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)+175	302	272	143	75
6	Novartis Company	468	94 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML A Phase 2 Study of BGJ398 in Patients With Recurrent GBM A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas+91	374	186	231	20
7	Fudan University Shanghai Cancer Center Institution	457	122 A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.+119	335	91	285	106
8	Roche / Genentech Company	454	123 A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer+120	331	235	173	25
9	Bristol Myers Squibb Company	394	134 A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)+131	260	159	184	32
10	Pfizer (incl. Seagen) Company	364	95 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2+92	269	151	180	22
11	Memorial Sloan Kettering Cancer Center Institution	344	22 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma+19	322	8	316	67
12	Jiangsu Hengrui Pharmaceuticals Company	266	133 A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects+130	133	100	88	57
13	GSK Company	243	53 A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202+50	190	88	126	18
14	Johnson & Johnson Company	240	83 A Long-term Extension Study of PCI-32765 (Ibrutinib)A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma+80	157	120	86	24
15	Amgen Company	238	29 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC+26	209	126	104	8
16	Sanofi Company	210	38 (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer+35	172	70	125	7
17	AbbVie (incl. ImmunoGen, Capstan) Company	184	65 A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor+62	119	75	78	25
18	Fred Hutchinson Cancer Center Institution	183	9 A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden Hippocampal-avoidance craniospinal irradiation+6	174	2	172	37
19	Eli Lilly (incl. Loxo) Company	177	50 A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma+47	127	66	91	11
20	Dana-Farber Brigham Cancer Center Institution	176	18 Active After Cancer Trial APT (adjuvant paclitaxel-trastuzumab)ATEMPT+15	158	18	147	22
21	Tianjin Medical University Cancer Institute and Hospital Institution	172	32 A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo+29	140	8	136	30
22	Cancer Hospital, Chinese Academy of Medical Sciences Institution	172	33 A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy+30	139	20	125	30
23	Peking University Cancer Hospital Institution	168	19 Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients+16	149	23	138	33
24	Children's Oncology Group (COG) Cooperative group	160	31 A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations AALL0232+28	129	100	54	13
25	Alliance for Clinical Trials in Oncology Cooperative group	152	43 ACOSOG Z0011 (Alliance)Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer Alliance A021501+40	109	65	77	12
26	Incyte Company	141	26 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma+23	115	49	79	10
27	Mayo Clinic Institution	137	13 At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer+10	124	13	114	25
28	SystImmune / Sichuan Biokin Company	135	73 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC+70	62	54	39	32
29	Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Institution	134	14 Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma+11	120	6	117	17
30	SWOG Cancer Research Network Cooperative group	132	30 Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth DRAMMATIC+27	102	54	70	13
31	Takeda Company	125	22 A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)+19	103	48	68	8
32	NRG Oncology Cooperative group	123	34 CIRCULATE-US Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer+31	89	75	48	9
33	Siteman Cancer Center, Washington University Institution	122	11 Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer+8	111	4	108	18
34	UNICANCER Cooperative group	120	31 Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme+28	89	52	58	18
35	EORTC Cooperative group	111	13 CATNON (EORTC 26053-22054)CCTG CE.6 / EORTC 26062-22061 (Perry trial)Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia+10	98	62	52	8
36	Peking Union Medical College Hospital Institution	111	16 A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.+13	95	21	82	20
37	City of Hope Institution	110	10 Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study+7	100	3	99	27
38	Gilead Sciences (incl. Kite) Company	110	35 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer ASCENT+32	75	44	48	5
39	CSPC Pharmaceutical Group Company	110	41 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer+38	69	51	42	18
40	Daiichi Sankyo Company	108	53 A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma A Study of DS-3939a in Participants With Solid Tumors+50	55	53	31	13
41	Massachusetts General Hospital Cancer Center Institution	107	10 COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury+7	97	9	90	16
42	Bayer Company	106	23 A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer+20	83	51	48	3
43	Ruijin Hospital Institution	105	12 Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metast HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer+9	93	10	84	29
44	The First Affiliated Hospital with Nanjing Medical University Institution	105	12 A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer+9	93	10	85	35
45	Akeso Company	101	47 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer+44	54	37	36	27
46	Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Cooperative group	100	15 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma+12	85	34	58	12
47	Regeneron Company	99	40 A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve+37	59	38	38	22
48	ECOG-ACRIN Cancer Research Group Cooperative group	97	23 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions CHAARTED (E3805)+20	74	39	52	9
49	Boehringer Ingelheim Company	91	14 A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit+11	77	43	42	7
50	Moffitt Cancer Center Institution	88	5 A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC+2	83	2	82	16
51	Institute of Hematology & Blood Diseases Hospital, China Institution	84	1 Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia	83	10	77	37
52	Second Affiliated Hospital, Zhejiang University, School of Medicine Institution	84	17 Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab+14	67	9	63	37
53	BeOne Medicines (formerly BeiGene) Company	83	38 A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat+35	45	38	28	12
54	Zhejiang Cancer Hospital Institution	79	9 Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer+6	70	10	63	18
55	Astellas Company	78	26 A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer+23	52	37	30	9
56	Samsung Medical Center Institution	77	3 Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma PULSAR in Systemic Therapy for Pancreatic Cancer	74	8	68	4
57	Robert H. Lurie Comprehensive Cancer Center of Northwestern University Institution	75	6 BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors+3	69	4	66	5
58	Severance Hospital, Yonsei University Institution	75	8 A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer+5	67	3	65	9
59	Assistance Publique - Hôpitaux de Paris Unmapped	73	5 Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome GRAALL-2005+2	68	31	44	13
60	National Institute of Allergy and Infectious Diseases (NIAID) Institution	72	0	72	13	61	13
61	Princess Margaret Cancer Centre Institution	70	10 A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC+7	60	8	58	9
62	Gustave Roussy Institution	70	17 A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat ESTIMABL2 First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.+14	53	26	38	15
63	St. Jude Children's Research Hospital Institution	69	8 Childhood Cancer Survivor Study (CCSS)Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies+5	61	15	51	9
64	West China Hospital Institution	69	20 A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer+17	49	10	46	14
65	Qilu Pharmaceutical Company	68	26 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer+23	42	38	21	13
66	Genmab Company	68	30 A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita+27	38	34	21	10
67	Henan Cancer Hospital Institution	67	6 Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer+3	61	2	60	11
68	University of California, San Francisco Institution	67	17 AI patient education for breast oncology AMMA portable scalp cooling Body composition and breast reconstruction outcomes+14	50	5	47	6
69	Shanghai Zhongshan Hospital Institution	67	19 A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer+16	48	7	44	10
70	University of Michigan Rogel Cancer Center Institution	64	2 Mastectomy Reconstruction Outcomes Consortium (MROC)Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial	62	1	61	7
71	Shanghai Henlius Biotech Company	64	28 A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer+25	36	17	30	17
72	Winship Cancer Institute of Emory University Institution	63	6 Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer+3	57	4	55	14
73	The First Affiliated Hospital of Soochow University Institution	62	1 Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients	61	19	50	24
74	UCLA Jonsson Comprehensive Cancer Center Institution	62	5 An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer PROFFi: fisetin and exercise to prevent frailty in breast cancer survivors Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer+2	57	7	51	13
75	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Institution	62	15 Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）+12	47	5	43	19
76	SCRI Development Innovations, LLC Unmapped	61	1 A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)	60	2	58	5
77	Stanford Health Care / Stanford Cancer Institute Institution	61	5 Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer+2	56	7	51	5
78	Roswell Park Comprehensive Cancer Center Institution	60	5 Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurre Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases+2	55	1	55	5
79	Merck KGaA (EMD Serono) Company	60	17 A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)+14	43	26	24	3
80	BioNTech Company	59	29 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer+26	30	14	24	16
81	Innovent Biologics Company	58	21 A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors+18	37	26	21	15
82	Fujian Cancer Hospital Institution	57	9 A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.+6	48	3	45	7
83	Jazz Pharmaceuticals Company	57	10 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o+7	47	29	23	7
84	University College London Hospitals / UCL Cancer Institute Institution	57	15 ABC-07 Add-Aspirin Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery+12	42	22	32	9
85	University of Chicago Medicine Comprehensive Cancer Center Institution	56	4 Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery+1	52	2	50	10
86	Abramson Cancer Center, University of Pennsylvania Institution	56	7 Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC+4	49	5	46	9
87	Canadian Cancer Trials Group (CCTG) Cooperative group	55	14 CCTG CE.6 / EORTC 26062-22061 (Perry trial)CHALLENGE (CCTG CO.21)EORTC 26981 / NCIC CE.3 (Stupp trial)+11	41	31	23	11
88	ImmunityBio Company	54	8 A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In+5	46	7	41	4
89	Sichuan Kelun-Biotech Company	53	33 A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities A Phase II Study of SKB571 in Patients With Lung Cancer+30	20	14	16	9
90	Weill Medical College of Cornell University Institution	51	3 A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	48	3	45	5
91	Hansoh Pharmaceutical Company	50	24 A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S+21	26	27	11	9
92	Yale School of Medicine / Yale Cancer Center Institution	49	3 Sac-TMT for Active TNBC Brain Metastases Saci Nivo Rela for TNBC Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels	46	1	45	12
93	Hutchmed Company	49	12 A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL+9	37	22	26	5
94	Case Comprehensive Cancer Center Institution	48	3 Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer	45	5	42	4
95	Netherlands Cancer Institute (NKI-AvL) Institution	48	11 Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy NADINA+8	37	16	31	8
96	Cancer Research UK Government or charity	48	29 A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer ABC-02 ACT II+26	19	26	16	6
97	Masonic Cancer Center, University of Minnesota Institution	47	1 Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy	46	1	46	7
98	Asan Medical Center Institution	47	4 DEBATE Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer NIFTY+1	43	8	36	5
99	Eisai Company	46	10 A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types+7	36	15	27	1
100	National Heart, Lung, and Blood Institute (NHLBI) Institution	45	0	45	8	37	1

(showing the first 100)

Sources

Registry studies are the phase 2 and 3 studies ClinicalTrials.gov returns for each product in the corpus (public/trials/*.json, fetched 2026-10-12), de-duplicated by NCT id and credited to the lead sponsor. Because they are found through products, sponsors of trials that name no corpus product are under-counted, and academic sponsors of investigator-initiated studies appear alongside the companies whose drugs they test.

Landmark trials are the curated trials in the corpus, credited to each party in the sponsor field (“AstraZeneca / Daiichi Sankyo” counts for both).

Names and cancers

Sponsor strings are normalised to company, institution and cooperative-group ids in src/data/sponsor-aliases.ts; acquired companies roll up to the acquirer. About 45% of study credits belong to names with no mapping yet and appear under the name as written. Cancers are matched from the registered condition text to corpus cancers by name and alias; a study counts under a cancer only when the text names it.

Compare with trial leadership, which ranks institutions by their presence in the landmark trials, and the company scorecards.